A general linear model, adjusting for age, sex, type of IBD, and number of vaccines, was used to assess differences in long-term IFN-γ (IU/mL) levels among the three treatment groups: anti-TNF monotherapy, combo, and thiopurine. This evidence concerns the gene IFNG and inflammatory bowel disease.